Document is current
Any future updates will be listed below
-
Authors
Arrieta, Oscar https://orcid.org/0000-0002-1164-3779
Lara-Mejía, Luis
Rios-Garcia, Eduardo https://orcid.org/0000-0002-2422-1671
Caballé-Perez, Enrique
Cabrera-Miranda, Luis
Ramos-Ramírez, Maritza
Dávila-Dupont, David
Cardona, Andrés F.
Cruz-Rico, Graciela
Remon, Jordi https://orcid.org/0000-0002-9462-875X
Garcilazo-Reyes, Alexandra
Rosell, Rafael
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 4 May 2025
First Online: 16 May 2025
Competing interests
: O.A. reports personal fees from Pfizer, Lilly, Merck, and Bristol Myers Squibb, and grants and personal fees from Astra Zeneca, Boehringer Ingelheim, and Roche. L.L.-M. has participated as a speaker for Astra Zeneca, Roche, Pfizer, Takeda, Janssen Cilag and Boehringer Ingelheim and personal fees from Janssen Cilag, Pfizer, Takeda, and Roche. A.F.C.: reports grants from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb and The Foundation for Clinical and Applied Cancer Research—FICMAC., other from Pfizer, Boehringer Ingelheim, Astra Zeneca, MSD, BMS, Celldex, Roche, personal fees from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly and Foundation for Clinical and Applied Cancer Research—FICMAC, outside the submitted work. The remaining authors declare no conflicts of interest.
